Picture courtesy Twitter
Pune: Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) and Union Health ministry for full market authorization of its COVID-19 vaccine Covishield.
Adar Poonawalla, the CEO of SII, tweeted on Friday that the Indian government now has enough data to consider a full market authorization of Oxford-AstraZeneca’s COVID which is produced under the brand name Covishield by the Pune-based firm.
Once the drug regulator and government give the go-ahead, Covishield will be available in medical stores.
Since being approved by DGCI for emergency use in January 2021, Covishield along with Bharat Biotech’s indigenously manufactured Covaxin has been used in India’s massive inoculation programme.
SII, the world’s biggest vaccine maker, has till date supplied over 1.25 billion doses of Covishield, which most Indians have received.
SII currently makes 240 million doses per month and is ready to export ‘large volumes’ from January, Poonawalla told Reuters.
Perth: He hadn’t scored a Test century for 16 months. His previous 15 Test knocks…
Bhubaneswar: The members of BJD's minority cell staged a demonstration in front of Raj Bhavan…
Bhubaneswar: Dense fog reduced visibility in Odisha's Rourkela while moderate fog engulfed Koraput, Bhawanipatna and…
Mumbai: Shreyas Iyer may be out of the Indian team currently, but the dashing right-handed…
Bhubaneswar: A rare and exquisitely crafted Filigree boat made of pure silver from Odisha was…
New Delhi/Bhubaneswar: Prime Minister Narendra Modi will participate in the ‘Odisha Parba 2024’ programme on…
New Delhi: A fresh application was filed before the Supreme Court on Sunday urging the…
Bhubaneswar: Chief Minister Mohan Majhi disbursed the first instalment of Rs 5,000 under Subhadra Yojana…